Making the case for molecular staging of malignant pleural mesothelioma.
Malignant pleural mesothelioma is an aggressive malignancy for which surgical treatment is an option for a subset of patients. A gene ratio test based on the relative expression levels of four genes has been validated in clinical trials to predict which patients will benefit from surgical therapy. A description of the test properties and the independent predictors for outcome are provided.
Bueno
Raphael
R
Division of Thoracic Surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. Rbueno@partners.org
D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D001706:Biopsy; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008654:Mesothelioma / Q000737:chemistry / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000601:surgery; D025202:Molecular Diagnostic Techniques; D009367:Neoplasm Staging / Q000379:methods*; D018579:Patient Selection; D010997:Pleural Neoplasms / Q000737:chemistry / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D018570:Risk Assessment; D019616:Thoracic Surgical Procedures; D016896:Treatment Outcome
D014408:Biomarkers, Tumor